Get started
Author

Ninghuan Li

Observed name: LI Ninghuan
ORCID: 0009-0008-9557-3923
Observed ORCID: 0009-0008-9557-3923
OpenAlex ID: A5030383098
Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model
2019 · Meiqi Zhao, Manyu Luo, et al. · Biomedicine & Pharmacotherapy · 35
PDF
Purification of inclusion bodies using PEG precipitation under denaturing conditions to produce recombinant therapeutic proteins from Escherichia coli
2017 · Huanhuan Chen, Ninghuan Li, et al. · Applied Microbiology and Biotechnology · 11
A novel self-cleavable tag Zbasic–∆I-CM and its application in the soluble expression of recombinant human interleukin-15 in Escherichia coli
2016 · Siwei Shi, Huanhuan Chen, et al. · Applied Microbiology and Biotechnology · 11
Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies
2022 · Jie Wang, Chen Li, et al. · Cancer Immunology Immunotherapy · 10
A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2025 · Huan Zhang, Fufan He, et al. · Molecular Cancer Therapeutics · 9
Abstract LB055: IBI3001: A potentially first-in-class site-specifically conjugated B7-H3/EGFR bispecific ADC for multiple solid tumors
2024 · Jian Guan, Xiao Zhang, et al. · Cancer Research · 5
B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities
2026 · Jian Guan, Tiongsun Chia, et al. · Nature Communications · 3
PDF
Abstract 344: IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models
2025 · Xiguang Zhang, Yanping Jin, et al. · Cancer Research · 3
Abstract LB056: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors
2024 · Jian Guan, Shuaixiang Zhou, et al. · Cancer Research · 2
Abstract LB222: Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors
2025 · Bo Wang, Jiakai Xing, et al. · Cancer Research · 1
Impact of IBI3017, an innovative bispecific anti-Trop2 and B7H3 antibody-drug conjugate, on anti-tumor efficacy in a wide range of tumors.
2026 · Bo Wang, Bin Li, et al. · Journal of Clinical Oncology
PDF
IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer
2026 · Yang Liu, Lei Cao, et al. · Cancer Immunology Immunotherapy
Supplementary Figure S7 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
PDF
Supplementary Figure S2 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
PDF
Supplementary Figure S5 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
Supplementary Figure S10 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
Supplementary Figure S6 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
Supplementary Figure S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
PDF
Supplementary Figure S11 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
PDF
Supplementary Table S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
Supplementary Figure S12 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
Supplementary Figure S9 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
Supplementary Figure S3 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
PDF
Data from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
Supplementary Figure S4 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026 · Huan Zhang, Fufan He, et al.
PDF
Works count: 29
Citation count: 90
H-index: 5
I10-index: 4
Year
Topic
Type